Rhythm Pharmaceuticals diskutieren
Rhythm Pharmaceuticals
WKN: A2H5A0 / Symbol: RYTM / Name: Rhythm Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
81,50 €
-1,21 %
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at HC Wainwright from $100.00 to $110.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $129.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $95.00 to $122.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $136.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $120.00 to $145.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at HC Wainwright from $110.00 to $123.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $145.00 to $148.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Royal Bank Of Canada. They set an "outperform" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Needham & Company LLC from $148.00 to $139.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Wells Fargo & Company from $145.00 to $136.00. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Neueste Beiträge
Barrington_Research in Anika Therapeutics diskutieren